



STATE OF TENNESSEE
BUREAU OF TENNCARE
DEPARTMENT OF FINANCE AND ADMINISTRATION
729 CHURCH STREET
NASHVILLE, TENNESSEE 37247-6501

Memorandum

DATE: August 21, 2003

TO: All TennCare Pharmacy Advisory Committee Members

FROM: Dr. David O. Hollis, TennCare

RE: TennCare Pharmacy Advisory Committee Meetings

I would like to thank you for volunteering to serve on the TennCare Pharmacy Advisory Committee. As you know, this committee will advise the TennCare Bureau on the development and implementation of the TennCare preferred drug list (PDL).

The first meeting of the committee will be held on August 28, 2003 at 9:00am CDST in the auditorium conference room located in the Downtown Nashville Public Library on Church Street. The first meeting will be organizational in nature as we discuss committee bylaws and review a presentation from ACS (Consultec) regarding the PDL development process and supplemental rebates. The second and third meetings will be held in the auditorium of the Tennessee State University's downtown Nashville campus at 10th Avenue North and Charlotte.

In order to help you adjust your schedules for future committee meetings, the following dates have been scheduled:

Phase I	September 8, 2003 (by noon EST) Supplemental rebate submission deadline September 11, 2003 TennCare Pharmacy Advisory Committee meeting October 15, 2003 implementation of hard edits
Phase II	September 29, 2003 (by noon EST) Supplemental rebate submission deadline October 9, 2003 TennCare Pharmacy Advisory Committee meeting November 15, 2003 implementation of hard edits
Phase III	October 31, 2003 (by noon EST) Supplemental rebate submission deadline November 12, 2003 TennCare Pharmacy Advisory Committee meeting December 15, 2003 implementation of hard edits

The TennCare PDL will be implemented in three phases, with each phase consisting of about ten therapeutic categories. Below you will find a listing of the therapeutic categories currently assigned to each phase.

Phase I (for October 15, 2003 implementation)

Gastric Acid Secretion Reducers
Lipotropics/Bile Acid Sequesterants
Hypotensives, ARBs
Hypotensives, ACE Inhibitors
Calcium Channel Blocking Agents
NSAIDS, Cyclooxygenase Inhibitor-Type
Beta-Adrenergic Blockers
Alpha/Beta- Adrenergic Blocking Agents
ACEI/CCB Combos
Antihistamines

Phase II (for November 15, 2003 implementation)

Narcotic Analgesics
Platelet Aggregation Inhibitors
Hypoglycemics, Insulin-Response Enhancer
Insulins
Bone Resorption Inhibitors
Antimigraine Preparations
Skeletal Muscle Relaxants
Hypoglycemics, Insulin-release stimulant
Urinary Tract Antispasmodic
Hypoglycemic, biguanide type

Phase III (for December 15, 2003 implementation)

Beta-Adrenergic Agents
Quinolones
Nasal Steroids
Estrogenic Agents
Glucocorticoids (inhaled and oral)
Leukotriene receptor antagonist
Potassium Replacement
Penicillins
Miotics & other
Macrolides
Anitemetic/Anitvertigo
Antifungals, oral
Antivirals, general

I am also enclosing a contact information sheet that I would like each of you to complete and return via email to Leo Sullivan at leo.sullivan@state.tn.us or facsimile 615-741-0882 . Thanks you for your valuable participation in the TennCare program and your willingness to serve on the TennCare Pharmacy Advisory Committee. I look forward to seeing you on August 28th.